llumina on Thursday forecast core business revenue to be nearly flat in the coming year compared to 2023 amid subdued demand for its genetic testing tools and diagnostics products. The San Diego-based ...

Solexa (www.solexa.com) claims that its new technology will transform sequencing by reducing cost and increasing throughput. “Our technology will offer a hundred-fold improvement in productivity and a ...

Bangalore (Reuters) - Companies that make the gene-sequencing devices used in scientific research face a tough few years as potential cuts to the U.S. federal budget squeeze funding to its main ...

SHENZHEN, China, Feb. 8, 2024 /PRNewswire/ -- MGI Tech, a company committed to building core tools and technology to lead life science, today announced its nomination as a finalist for the 2024 Edison ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

Illumina (NASDAQ:ILMN) on Monday lowered its adjusted profit outlook and cut spending costs for 2025 as the company grapples with a Chinese ban on its gene sequencers. Illumina now expects fiscal 2025 ...

Most biopharma players need access to gene sequencing services. Illumina is facing a handful of headwinds, but it's still the market leader. Bionano Genomics is unproven but expanding quickly. So ...

With shares of the gene sequencing giant Illumina (NASDAQ: ILMN) collapsing by 53% over the last three years due to a combination of a botched acquisition attempt and weakness in its core business, ...

SANTA CLARA, CA--(Marketwire - Oct 31, 2012) - NVIDIA® Tesla® GPU accelerators are enabling Life Technologies Corporation's new Ion Proton™ System to accelerate primary genome-sequence analysis-- the ...

Elucidating the relationship between the sequences of non-coding regulatory elements and their target genes is key to understanding gene regulation and its variation between plant species and ecotypes ...